Hober Biotech

Hober Biotech AB is a Swedish biotechnology company founded by Professor Sophia Hober of the Royal Institute of Technology (KTH). The company specializes in the development of novel affinity proteins and scaffold-based technologies for diagnostic and therapeutic applications, primarily in oncology. Its core technology, the ADAPT platform, utilizes small, stable protein domains derived from albumin-binding domains to create highly specific binders for cancer biomarkers. The company's lead program, ADAPT6, is a radiopharmaceutical imaging agent targeting HER2-expressing tumors and has successfully completed Phase 1 clinical trials. Hober Biotech AB operates primarily as an IP-focused entity, licensing its innovative protein scaffolds to partners for further clinical development and commercialization.